FDA Adverse Event Injury Summary report: N

XEN 45 GTS

MDR report key: 22187920 · Received June 11, 2025

Report

Report Number
3011299751-2025-00076
Event Type
Injury
Date Received
June 11, 2025
Date of Event
May 19, 2025
Report Date
June 11, 2025
Manufacturer
ALLERGAN (IRVINE)
Product Code
KYF
UDI-DI
10888628032439
PMA / PMN Number
K161457
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
SP
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ARTICLE CITATION: BERTOLANI, Y., RIGO-QUERA, J., SÁNCHEZ-VELA, L., PUJOL-CARRERAS, O., AMILBURU, M., DOU, A., & CASTANY, M. (2025). EFFICACY AND SAFETY OF OPEN-CONJUNCTIVA AB EXTERNO 63 M VS. 45 M XEN® GEL STENT IN GLAUCOMA SURGERY: ONE-YEAR FOLLOW-UP. JOURNAL OF CLINICAL MEDICINE, 14(10), 3545. HTTPS://DOI.ORG/10.3390/JCM14103545. MULTIPLE REQUESTS FOR FURTHER INFORMATION HAVE BEEN MADE. ABBVIE HAS RECEIVED NO RESPONSE FROM THE AUTHORS. THE EVENT OF HIGH INTRAOCULAR PRESSURE IS A KNOWN POTENTIAL ADVERSE EVENT ADDRESSED IN THE PRODUCT LABELING.

Description of Event or Problem · 0

REVIEW OF THE ARTICLE "EFFICACY AND SAFETY OF OPEN-CONJUNCTIVA AB EXTERNO 63 M VS. 45 M XEN® GEL STENT IN GLAUCOMA SURGERY: ONE-YEAR FOLLOW-UP" FROM THE JOURNAL OF CLINICAL MEDICINE NOTED THE FOLLOWING EVENTS "0.39 ANTIHYPERTENSIVE DRUGS ON AVERAGE WERE REQUIRED; NEEDLING PROCEDURE REQUIRED IN 5 EYES; 2 EYES REQUIRED SURGICAL BLEB REVISION DUE TO FIBROSIS; 3 EYES REQUIRED SECONDARY GLAUCOMA PROCEDURE TO ACHIEVE OPTIMAL IOP CONTROL; 2 EYES HAD SELF-LIMITED HYPHEMA; 1 EYE HAD WOUND LEAK TREATED WITH A CONTACT LENS; 1 EYE HAD ANTERIOR SEGMENT SYNDROME (TASS) WITH IOP SPIKE, URRETZ-ZAVALIA SYNDROME AND CORNEAL DECOMPENSATION REQUIRING DESCEMET STRIPPING AUTOMATED ENDOTHELIAL KERATOPLASTY (DSAEK) AND TRABECULECTOMY; 8 EYES HAD HYPOTONY; 1 EYE HAD SEROUS CHOROIDAL DETACHMENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
87665 XEN 45 GTS IMPLANT, EYE VALVE KYF ALLERGAN (IRVINE) NI 10888628032439

Patients

Seq Age Sex Outcome Treatment
1 70 YR Male Required Intervention